UPDATE 2-AstraZeneca lung cancer study fails in big setback for company

LONDON, July 27 (Reuters) – AstraZeneca’scombination of two injectable immunotherapy drugs, durvalumaband tremelimumab, failed to help patients as hopedin a closelywatched advanced lung cancer trial, the British company said onThursday.
The post UPDATE 2-AstraZeneca lung cancer study fails in big setback for company appeared first on RocketNews | Top News Stories From Around the Globe.